据称阿斯利康曾探讨与百时美施贵宝合并
· fortune.com
市值达 1330 亿美元的百时美施贵宝 (Bristol Myers Squibb) 可为阿斯利康提供更大的美国市场立足点。
AstraZeneca Plc has explored an acquisition of Bristol Myers Squibb Co., in a megadeal that would create one of the world’s largest drugmakers, according to p...